Abdel-Rahman S M, Kauffman R E. The integration of pharmacokinetics and pharmacodynamics: understanding dose-response [J]. Annu Rev Pharmacol Toxicol, 2004, 44:111.
[2]
Csajka C, Verotta D. Pharmacokinetic-pharmacodynamic modelling: history and perspectives[J]. J Pharmacokinet Pharmacodyn, 2006, 33(3): 227.
Han M, Fu S, Fang X L. Comparison between the characteristics of absorption and pharmacokinetic behavior of ginsenoside Rg1 and ginsenoside Rb, of Panax notoginseng saponins[J]. Acta Pharm Sin, 2007, 42(8): 849.
[11]
Liu H, Yang J, Du F,et al. Absorption and disposition of ginsenosides after oral administration of Panax notoginseng extract to rats[J]. Drug Metab Dispos, 2009, 37(12): 2290.
[12]
Sheiner L B, Steimer J L. Pharmacokinetic/pharmacodynamic modeling in drug development[J]. Annu Rev Pharmacol Toxicol, 2000, 40: 67.
[13]
Derendorf H, Lesko L J, Chaikin P,et al. Pharmacokinetic/pharmacodynamic modeling in drug research and development [J]. J Clin Pharmacol, 2000, 40(12 Pt 2): 1399.
[14]
Leung K W, Cheng Y K, Mak N K, et al. Signaling pathway of ginsenoside-Rg1 leading to nitric oxide production in endothelial cells[J]. FEBS Lett, 2006, 580(13): 3211.
[15]
Yu J, Eto M, Akishita M, et al. Signaling pathway of nitric oxide production induced by ginsenoside Rb1 in human aortic endothelial cells: a possible involvement of androgen receptor[J]. Biochem Biophysi Res Communic, 2007, 353(3): 764.
[16]
Leung K W, Leung F P, Mak N K,et al. Protopanaxadiol and protopanaxatriol bind to glucocorticoid and oestrogen receptors in endothelial cells[J]. Br J Pharmacol, 2009, 156(4): 626.
[17]
Pan C, Huo Y, An X,et al. Panax notoginseng and its components decreased hypertension via stimulation of endothelial-dependent vessel dilatation[J]. Vascul Pharmacol, 2012, 56(3/4): 150.
[18]
Chu K M, Hu O Y, Shieh S M. Cardiovascular effect and simultaneous pharmacokinetic and pharmacodynamic modeling of pimobendan in healthy normal subjects[J]. Drug Metab Dispos, 1999, 27(6): 701.
[19]
Liu X Y, Wang B J, Yuan G Y,et al. Comparison of different pharmacodynamic models for pharmacokinetic-pharmacodynamic(PK-PD)modeling of carvedilol[J]. Acta Pharm Sin, 2009, 44(4): 406.
Sheiner L B, Stanski D R, Vozeh S, et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine[J]. Clin Pharmacol Ther, 1979, 25(3): 358.
[22]
Holford N H, Sheiner L B. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models [J]. Clin Pharmacokinet, 1981, 6(6): 429.
[23]
郭文婧. 生脉方药代动力学研究[D]. 杭州:浙江大学,2012.
[24]
Zhan S Y, Shao Q, Liu L,et al. A simple and accurate method to determine nitrite and nitrate in serum based on high-performance liquid chromatography with fluorescence detection[J]. Biomed Chromatogr, 2013, 27(11): 1547.
[25]
Xu Q F, Fang X L, Chen D F. Pharmacokinetics and bioavailability of ginsenoside Rb1 and Rg1 from Panax notoginseng in rats[J]. J Ethnopharmacol, 2003, 84(2/3): 187.
